BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating AN2 Therapeutics, Inc. (NASDAQ:ANTX) for potential securities law violations. Investors who have lost money in their AN2 Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/antx.
What is this all about?
Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.
Shares of AN2 Therapeutics stock dropped more than ...